3
Announcements
Trials
Browse
Landscape
Status
Recruiting
56
Active not recruiting
54
Completed
53
Unknown
36
Not yet recruiting
22
Terminated
12
Withdrawn
2
Suspended
1
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Conditions
EGFR T790M Mutation Positive NSCLC
1
Interventions
ceritinib
2
tazemetostat
1
taletrectinib
1
sotorasib
1
rovalpituzumab tesirine
1
rociletinib
1
pegilodecakin
1
patritumab deruxtecan
1
osimertinib
1
lorlatinib
1
dabrafenib
1
capmatinib
1
brigatinib
1
belagenpumatucel L
1
alectinib
1
Suspensions
1
Powders
1
Paclitaxel
1
Nivolumab
1
Crizotinib
1
BID protein, human
1
AM0010
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
No longer available
×
osimertinib
×
Thoracic
×
Clear all
NCT02451852
2016-07-14
AZD9291 US Expanded Access Program
AstraZeneca
No longer available